Blood Transfusions and Prognosis in Colorectal Cancer

  • Harlaar J
  • Gosselink M
  • Hop W
  • et al.
N/ACitations
Citations of this article
53Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background Blood transfusions may adversely affect the prognosis of patients treated surgically for cancer, although definite proof of this adverse effect has not been reported. Methods We carried out a randomized trial to investigate whether the prognosis in patients with colorectal cancer would be improved by a program of autologous blood transfusion as compared with the current practice of allogeneic transfusion. Patients in the autologous-transfusion group were required to donate two units of blood before surgery. Results A total of 475 patients were evaluated. We found no significant difference in prognosis between the allogeneic-transfusion group (236 patients) and the autologous-transfusion group (239 patients); colorectal cancer-specific survival rates at four years were 67 percent and 62 percent, respectively (P = 0.39). Among the 423 patients who underwent curative surgery, 66 percent of those in the allogeneic-transfusion group and 63 percent of those in the autologous-transfusion group had no ...

Cite

CITATION STYLE

APA

Harlaar, J. J., Gosselink, M. P., Hop, W. C. J., Lange, J. F., Busch, O. R. C., & Jeekel, H. (2012). Blood Transfusions and Prognosis in Colorectal Cancer. Annals of Surgery, 256(5), 681–687. https://doi.org/10.1097/sla.0b013e318271cedf

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free